Inovio partners with Advaccine to make and sell COVID-19 vaccine in China

Inovio partners with Advaccine to make and sell COVID-19 vaccine in China 8:01 AM (Reuters) – China’s Advaccine Biopharmaceuticals Suzhou Co Ltd will manufacture and sell Inovio Pharmaceuticals Inc’s COVID-19 vaccine candidate in the country, the companies said on Monday. Advaccine will have the exclusive right to Inovio’s vaccine candidate, INO-4800, in China. The vaccine is currently being tested in two mid-to-late stage trials, one in China and the other in the United States. Inovio will receive an upfront payment of $3 million and an aggregate of $108 million upon the achievement of specified development and sales-based milestones. It will…